Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Danaher Corporation (NYSE: DHR) announced plans to separate its Environmental & Applied Solutions (EAS) segment into an independent, publicly traded entity. This separation, expected to be tax-free for shareholders and completed in Q4 2023, will focus on Danaher's Water Quality and Product Identification businesses. EAS, projected to generate approximately $4.7 billion in revenue in 2021, aims for enhanced investment opportunities with a resilient business model and a dedicated leadership team. Jennifer Honeycutt will serve as CEO of EAS post-separation.
On September 13, 2022, Danaher Corporation (NYSE: DHR) declared a quarterly cash dividend of $0.25 per share for common stock, payable on October 28, 2022, to shareholders of record on September 30, 2022. Additionally, a dividend of $12.50 per share for its 5.00% Series B Mandatory Convertible Preferred Stock was announced, payable on October 15, 2022, also to shareholders recorded by September 30, 2022.
Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting on September 15, 2022, at 12:00 p.m. ET. The event will take place at the Cytiva facility in Marlborough, Massachusetts, featuring President & CEO Rainer M. Blair and VP Emmanuel Ligner. Interested parties can access the webcast and presentation slides in the
On July 25, 2022, Beckman Coulter announced a partnership with Massachusetts General Hospital to validate the Monocyte Distribution Width (MDW) biomarker for identifying severe pediatric infections. Funded by BARDA, the multi-center trial focuses on children under 15 with high fevers, aiming to enhance early detection of those at risk for hospitalization. This initiative leverages MDW's existing FDA clearance for adult sepsis, expanding its clinical utility in emergency departments, potentially allowing for quicker, informed treatment decisions without unnecessary testing.
Danaher Corporation (NYSE: DHR) reported its Q2 2022 results, showing net earnings of $1.7 billion or $2.25 per diluted share, a 1.5% decrease year-over-year.
However, non-GAAP adjusted diluted net earnings increased by 12% to $2.76 per share. Revenues rose 7.5% to $7.8 billion, with a core revenue growth of 9.5%. Operating cash flow stood at $2.0 billion, while non-GAAP free cash flow reached $1.7 billion. For Q3, the company expects high-single digit growth in core revenue.
Nordson Corporation (Nasdaq: NDSN) announced a strategic realignment of its business segments effective August 1, 2022. The new structure includes three segments: Industrial Precision Solutions (IPS), Medical and Fluid Solutions (MFS), and Advanced Technology Solutions (ATS). This change aims to enhance visibility in growing medical and electronics platforms. In fiscal 2021, IPS generated approximately $1.2 billion, MFS $0.6 billion, and ATS $0.5 billion in revenues. The company remains focused on top-tier growth with a commitment to innovative solutions across diverse end markets.
Danaher Corporation (NYSE: DHR) has appointed Feroz Dewan to its Board of Directors, increasing the board size from thirteen to fourteen members. Dewan, currently CEO of Arena Holdings Management, brings extensive experience from Tiger Global Management and Silver Lake Partners. His appointment aims to enhance Danaher's financial acumen and technology expertise, as noted by Chairman Steven M. Rales. Danaher is committed to innovation in healthcare, environmental and applied markets, supported by a team of approximately 80,000 associates.
Danaher Corporation (NYSE: DHR) will host a webcast for its second quarter 2022 earnings conference call on July 21, 2022, starting at 8:00 a.m. ET. The call, anticipating a duration of approximately one hour, will be accessible via the Investors section of Danaher's website. A replay will be available post-call until August 4, 2022. The earnings press release, along with slide presentations, will be posted online from 6:00 a.m. ET on the day of the call.
SciEX, part of Danaher Corporation (NYSE:DHR), has launched Zeno SWATH DIA, enhancing biomarker discovery through improved sensitivity and speed. The new system can quantify up to 2x the proteins in cell and plasma samples, significantly boosting clinical test development. Researchers can achieve large population-scale proteomic studies in weeks with 5-minute run-times, optimizing costs and sample usage. This advancement is expected to drive new therapies and precision medicine, reflecting a significant step forward in translational OMICS research.
SCIEX, a member of Danaher Corporation (NYSE:DHR), has launched SCIEX OS software v3.0 at ASMS 2022, aiming to enhance laboratory efficiency and integration. The software supports their mass spectrometry portfolio and introduces features such as Zeno SWATH DIA and stMRM, promoting superior data quality and workflow enhancements. The new Central Administration Console simplifies project management and security, while accessibility has been boosted with support for nine languages, enabling a global reach.